Know Labs Announces Expanded Technology Leadership in its Executive Team

Acceleration of Platform Development to Secure Multiple Strategic Partnerships

Know Labs Announces Expanded Technology Leadership in its Executive Team

Know Labs, Inc.
Jordyn Hujar
jordyn@knowlabs.co
Ph. (206) 629-6414

Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive diagnostics technology, announced today two additions to its executive leadership team. The new executives are John Cronin and Dominic Klyve, Ph.D. They are tasked with both furthering the development of the Company’s non-invasive diagnostic technology platform and building relationships with potential strategic partners.

“John and Dominic bring extensive technology leadership and research experience to the Know Labs team,” said Ron Erickson, CEO. “In their new roles they provide intellectual leadership to both drive our technology development and real-world business acumen to assist in bringing our platform to market through strategic relationships with global leaders in the med tech, pharma and consumer marketplace.”

John Cronin joins the day-to-day team as Interim Chief Technology Officer. Previously, Cronin was elected as a member of the Company’s Board of Directors. He has been a strategic advisor and consultant to Know Labs, supporting the Company’s expanding patent portfolio and securing its global leadership as the top patent holder in the non-invasive blood glucose monitoring category. Cronin will oversee the Company’s product development and technology strategy and help the Know Labs team develop test protocols to address research and development questions. In addition, Cronin spearheads the Know Labs “skunkworks” activities which explores new applications for the Company’s platform technology, an example of which is the recently announced automobile steering wheel application of our sensor platform. Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin began his career at IBM where he was the sole inventor of breakthrough chip design technology and later, he became IBM’s top inventor. He went on to create the IBM Patent Factory, growing IBM’s patent portfolio from ninth to first in the world catapulting IBM’s IP licensing from $30 million to over $2 billion a year. Today, Mr. Cronin has approximately 1800 patents and applications worldwide.

Dominic Klyve, Ph.D., a long-time consultant and previous employee of the Company, joins as Chief Science Officer. Dr. Klyve previously served as lead data scientist at Know Labs. As Chief Science Officer, he will be responsible for leading the research and development team in its efforts to build the first non-invasive glucose monitor. Klyve has been an author on several studies published by Know Labs, including its most recent peer-reviewed study published in IEEE Sensors Journal detailing historical developments and limitations with RF-based sensing technologies, and the distinctiveness of Know Labs’ sensor architecture and trade-secret prediction machine learning algorithm. Klyve is the author of more than 80 peer-reviewed publications in several fields of science and mathematics and has served as Principal Investigator on grants from the National Science Foundation (among others) worth over $1.5 million. He holds a professorship at Central Washington University, where he is currently on sabbatical, and is a former Editor of the College Mathematics Journal.

For more information on Know Labs, visit www.knowlabs.co.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s first expected application of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.